SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors [Yahoo! Finance]
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
SAB Biotherapeutics Provides SAB-142 Trial Update [Yahoo! Finance]